OS-01 (Peptide 14)

What is OS-01 Peptide?#

OS-01, also known as Peptide 14 or Decapeptide-52, is a senotherapeutic peptide developed by OneSkin, a biotechnology company focused on skin longevity. It was identified through a phenotypic screen of over 900 novel peptide candidates designed to target cellular senescence -- the process by which cells permanently stop dividing and accumulate with age, contributing to tissue dysfunction, chronic inflammation, and visible aging.

OS-01 is notable as the first senotherapeutic compound to be commercialized in consumer skincare products. OneSkin's product line includes face, body, and eye formulations containing OS-01 as the active ingredient. These are marketed as cosmetic topical supplements and are not FDA-approved drugs.

The peptide has been evaluated in three published clinical trials and one preclinical study, all conducted by OneSkin researchers or affiliates. While the results are promising for a cosmetic ingredient, the proprietary nature of the peptide sequence and industry sponsorship of all studies are important context for interpreting the evidence.

Mechanism of Action#

OS-01 functions as a senomorphic agent -- it modulates the behavior of cells approaching senescence rather than selectively killing senescent cells (as senolytics do). The primary mechanism involves modulation of protein phosphatase 2A (PP2A):

• PP2A activation: PP2A is a holoenzyme involved in genomic stability, DNA repair, and senescence pathways. OS-01 modulates PP2A activity, specifically targeting the PPP2R1A scaffold regulatory subunit, which acts as an upstream modulator of Akt signaling
• Cell cycle and DNA repair: At the single-cell level, OS-01 modulates gene expression to prevent senescence progression by arresting the cell cycle at appropriate checkpoints and enhancing DNA damage repair capacity
• p16INK4a reduction: OS-01 reduces expression of CDKN2A (p16INK4a), a key senescence marker, in both the dermal and epidermal layers of human skin
• SASP reduction: Treatment decreases the senescence-associated secretory phenotype (SASP), reducing pro-inflammatory cytokine production by senescent cells

This senomorphic approach differs fundamentally from senolytic peptides like FOXO4-DRI, which interfere with p53-FOXO4 interactions to trigger apoptosis in senescent cells. OS-01 instead prevents cells from progressing into late-stage senescence while supporting repair of pre-senescent cells.

Research Overview#

OS-01 has been studied in one preclinical publication and three clinical trials, all published between 2023 and 2025:

• Preclinical (npj Aging, 2023): Identified Peptide 14 through two-step phenotypic screening. Demonstrated efficacy across four senescence models (progeria, chronological aging, UV radiation, etoposide). Showed reduced DNA methylation age in ex vivo skin and outperformed retinol on epidermal thickness markers
• Clinical Trial 1 (J Cosmet Dermatol, 2024): Split-face, double-blinded, vehicle-controlled study (n=22) showing improved skin barrier function with OS-01 formulation
• Clinical Trial 2 (J Cosmet Dermatol, 2025): Larger RCT (n=60, women aged 60-90) demonstrating 70% skin improvement vs 42% control, reduced TEWL by 41.49%, decreased systemic IL-8, and slowed biological aging by GlycanAge
• Clinical Trial 3 (Int J Cosmet Sci, 2025): Periorbital study (n=22) showing 25.58% improved elasticity, 32.49% increased hydration, and 17.33% decreased TEWL

All studies were industry-sponsored by OneSkin or affiliated researchers. The peptide sequence remains proprietary, limiting independent replication.

Important Considerations#

OS-01 occupies an unusual position at the intersection of cosmetic products and aging research:

• Regulatory status: OS-01 is sold as a cosmetic ingredient, not a pharmaceutical. It has not undergone FDA drug approval processes and is not subject to pharmaceutical-grade regulatory scrutiny
• Industry sponsorship: All published studies have been conducted by OneSkin researchers or close affiliates. Independent replication has not been reported
• Proprietary sequence: The exact amino acid sequence of OS-01 is not publicly disclosed, which prevents independent synthesis and verification
• Cosmetic publication context: Clinical trials have been published in cosmetic dermatology and cosmetic science journals rather than clinical pharmacology or aging-specific journals
• Topical application only: All evidence pertains to topical formulations; systemic effects observed (IL-8, GlycanAge) from topical application are preliminary and mechanistically unclear

Key Research Findings#

Senotherapeutic peptide treatment reduces biological age and senescence burden in human skin models, published in npj Aging (Zonari A et al., 2023; PMID: 37217561):

• Peptide 14 (OS-01) reduced senescence across HGPS, UV, chronological aging, and etoposide models
• Mechanism involves PP2A modulation to prevent senescence progression
• Reduced DNA methylation age in ex vivo human skin samples

OS-01 Peptide Topical Formulation Improves Skin Barrier Function and Reduces Systemic Inflammation Markers, published in Journal of Cosmetic Dermatology (Zonari A et al., 2025; PMID: 40193112):

• 70% skin improvement in OS-01 group vs 42% in control group (n=60)
• 41.49% improvement in transepidermal water loss
• Significant decrease in circulating IL-8 levels

Related Reading#

• OS-01 Peptide research studies and evidence
• OS-01 Peptide dosing and application
• OS-01 Peptide side effects profile
• FOXO4-DRI research guide
• Epitalon research guide